Celeste Miranda is at the forefront of cannabinoid medicine and research. As the founder and CEO at Celeste Miranda & Associates, the CEO of MACE Media Group, and now the driving force behind the Journal of Cannabinoid Medicine, Miranda has been tirelessly working to bring cannabinoid research into the hands of consumers and policymakers.
Miranda, a cannabis patient herself, knows the power of cannabinoid medicine. For years she has taken CBD to treat Multiple Sclerosis and has found it especially useful for treating the spasticity in her legs. Through this direct experience, she developed CBD Health and Wellness Magazine. A publication with a consumer orientation connecting entrepreneurs, patients, professionals and physicians.
The tremendous response to this magazine led her into a career of cannabinoid focused advocacy including the launch of several other publications, and the creation of the CBD Expo. For her, at these expos, the “Focus is always education. That’s number one, that’s why I’m here.”
Her industry connections have made it possible to launch her newest publication, the Journal of Cannabinoid Medicine. This publication is “a new platform for researchers to disseminate empirical research findings, with the aim that people everywhere have access to the medicines they need and use them rationally.”
Pushing for Change Through Research and Dissemination
MACE Media, the company behind the Journal of Cannabinoid Medicine, is already behind two other well-established publications in the cannabis space: Terpenes & Testing and Extraction Magazine. MACE is one of the “largest diversified media and information companies in cannabis.”
The Journal of Cannabinoid Medicine will serve as one of the first peer-reviewed databases of cannabinoid research. In the future, Miranda envisions it as a place for policymakers to source as they push for changes to legislation. As she sees it, one day, the body of work produced through this journal will help the FDA craft appropriate health claims for cannabinoids.
But Miranda confirms the magazine is, “Not just a playground for physicians and PhDs.” As many in the industry are well aware, expertise in cannabis doesn’t always mean a designation after your name. Anyone with the right experience, including physicians, researchers, scientists, and more, can submit to the extensive peer-review submission process. Submission is as easy as a click of a button.
Importantly while the publication follows a strict peer-review process, the online portal also serves as a source for other valuable insights into cannabinoid research. Its a database for intel on cannabinoid news and updates on studies published elsewhere.
A Multitiered Review Process, 9 Months in the Making
Miranda and the team behind the Journal of Cannabinoid Medicine are working on a global scale. They are seeking submissions from universities, cannabinoid research centers, physicians, and clinics around the world.
For those unfamiliar with the peer-review process, Miranda confirms it is no walk in the park. For a typical submission, it takes nine months to make it through to publication. Each submission, whether from an established name or a graduate student, goes through a multitiered process of reviewing and editing.
Initially, an editorial board, comprised of physicians and researchers reviews the paper for relevancy. If and when approved, the paper goes to a secondary peer-review board in charge of “ripping it up” to ensure validity. In follow up to the peer review, there is a third review by the editorial board and final approval by an advisory committee before publishing.
This extensive peer-review process is only one of the ways that the Journal for Cannabinoid Medicine is pushing the field of cannabinoid medicine beyond the consumer-oriented realm of publication today. As many realize, a peer-reviewed form of publication adds a significant level of legitimacy to the field.
While many patients have found cannabinoids medicine highly effective, more research is needed before policymakers, and medical professionals take these claims seriously. With the launch of the Journal of Cannabinoid Medicine, Miranda and the editorial board will be partially responsible for turning these cannabinoid rumors into policy actions.
As Miranda announced in a recent press release for the publication, “We hope to continue to educate the world about cannabinoids with the research and findings from industry leaders and medical professionals.” The journal as a big future ahead of it, acting as the go-to resource for legitimate developments in cannabinoid research.
